Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 5/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26012148 | 0.91 | DRD4 (0.55) | DRD4DRD2HTR2CDRD3MEN1 | |
| SCHEMBL26012437 | 0.91 | DRD4 (0.55) | DRD4DRD2HTR2CDRD3MEN1 | |
| SCHEMBL26012919 | 0.87 | SIGMAR1 (0.51) | DRD4DRD2HTR2CDRD3MEN1 | |
| SCHEMBL26014425 | 0.87 | DRD4 (0.43) | DRD4DRD2HTR2CDRD3MEN1 | |
| SCHEMBL26004506 | 0.86 | DRD4 (0.42) | DRD4DRD2HTR2CDRD3MEN1 | |
| SCHEMBL26004220 | 0.86 | SIGMAR1 (0.41) | DRD4DRD2HTR2CDRD3MEN1 | |
| SCHEMBL25354914 | 0.80 | ADRA2A (0.59) | DRD4DRD2HTR2CDRD3MEN1 | |
| SCHEMBL30623375 | 0.80 | ADRA2A (0.59) | DRD4DRD2HTR2CDRD3MEN1 | |
| SCHEMBL26012362 | 0.79 | MAPK1 (0.51) | DRD4DRD2HTR2CDRD3MEN1 | |
| SCHEMBL26012971 | 0.78 | DRD4 (0.47) | DRD4DRD2HTR2CDRD3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154314-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |